Physician profile
Binay Kumar
NPI 1811144504
$3,590.50
in general payments reported to CMS, 2019-2025
21 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $35.12 · 2021: $441 · 2022: $631 · 2023: $1,585 · 2024: $898.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,451 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,451.17 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $574.96 | 2023-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $551.93 | 2021-2024 | Xifaxan, Trulance |
| Astrazeneca Pharmaceuticals Lp | $414.15 | 2020-2024 | Farxiga, Breztri |
| Lilly USA, LLC | $378.29 | 2022-2024 | Jardiance, Mounjaro, Emgality |
| Novo Nordisk INC | $358.71 | 2022-2024 | Rybelsus, Ozempic, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $242.07 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $235.57 | 2022-2024 | Jardiance, Tradjenta |
| Amgen INC. | $183.94 | 2023-2024 | Otezla, Repatha |
| Exact Sciences Corporation | $168.86 | 2023-2024 | Cologuard Collection Kit |
| Daiichi Sankyo INC. | $119.32 | 2023-2024 | Injectafer |
| Mylan Specialty L.P. | $94.63 | 2023-2024 | Yupelri |
| Alnylam Pharmaceuticals INC. | $54.56 | 2023 | Givlaari |
| Glaxosmithkline, LLC. | $43.52 | 2020-2023 | Arexvy |
| Phathom Pharmaceuticals, INC. | $30.98 | 2024 | Voquezna |
| Covis Pharma Gmbh | $24.00 | 2023 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $22.45 | 2023 | Freestyle Libre 2 |
| Esperion Therapeutics, INC. | $20.02 | 2024 | Nexletol |
| Biohaven Pharmaceutical Holding Company Ltd. | $18.87 | 2022 | |
| Alk-Abello, INC | $18.53 | 2024 | Odactra, Grastek |
| Sanofi Pasteur INC. | $18.39 | 2023 | |
| Pfizer INC. | $16.75 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Binay Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.